Literature DB >> 27547134

Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future.

Ramsey M Wehbe, Ajay Yadlapati.   

Abstract

Entities:  

Keywords:  Administration, oral; anti-arrhythmia agents/therapeutic use; anticoagulants/administration & dosage/adverse effects/therapeutic use; atrial fibrillation/complications/drug therapy/epidemiology; attitude of health personnel; clinical trials as topic; practice guidelines as topic/standards; risk assessment/standards; risk factors; stroke/etiology/prevention & control

Mesh：

Substances：

Year:  2016        PMID： 27547134      PMCID： PMC4979382          DOI： 10.14503/THIJ-16-5785

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


× No keyword cloud information.
  44 in total

1.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.

Authors:  Anders Ingelgård; Jennifer Hollowell; Prabashni Reddy; Karen Gold; Kimbach Tran; David Fitzmaurice
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

3.  Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

Authors:  Jeffrey I Weitz; William Semchuk; Alexander G G Turpie; William D Fisher; Cindy Kong; Antonio Ciaccia; John A Cairns
Journal:  Clin Ther       Date:  2015-10-16       Impact factor: 3.393

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.

Authors:  Albert L Waldo; Richard C Becker; Victor F Tapson; Kevin J Colgan
Journal:  J Am Coll Cardiol       Date:  2005-10-10       Impact factor: 24.094

6.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

7.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

8.  Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.

Authors:  B F Gage; M Boechler; A L Doggette; G Fortune; G C Flaker; M W Rich; M J Radford
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

9.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  2 in total

1.  Atrial fibrillation in patients with first-ever stroke: Incidence trends and antithrombotic therapy before the event.

Authors:  Yo Han Jung; Young Dae Kim; Jinkwon Kim; Sang Won Han; Kyung-Yul Lee
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

2.  Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies.

Authors:  Manuel Anguita; Mariano de la Figuera; Alejandro I Pérez Cabeza; Carmen Suarez Fernández
Journal:  Drugs Context       Date:  2019-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.